Dysregulated cholesterol metabolism results in cholesterol accumulation in the liver of NAFLD patients (Puri et al., 2007; Caballero et al., 2009; Min et al., 2012), which can lead to NLRP3 inflammasome activation (Mridha et al., 2017), hepatic inflammation, and fibrosis (Ioannou, 2016). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.